Literature DB >> 14648134

Factors associated with the development of chorioretinal atrophy around choroidal neovascularization in pathologic myopia.

Ariko Kojima1, Kyoko Ohno-Matsui2, Satoshi Teramukai3, Takeshi Yoshida1, Yoko Ishihara4, Kanako Kobayashi1, Noriaki Shimada1, Kenjiro Yasuzumi1, Soh Futagami1, Takashi Tokoro1, Manabu Mochizuki1.   

Abstract

PURPOSE: To examine the influencing factors on the development of chorioretinal atrophy, which is the main cause of long-term visual decrease in myopic choroidal neovascularization (CNV), in a large series of highly myopic patients.
METHODS: Sixty-five patients (81 eyes) with myopic CNV were studied retrospectively. The influence of the patient's age, refractive error, axial length, visual acuity at onset of CNV, size of CNV, and grade of myopic retinopathy on the extent of chorioretinal atrophy more than 3 years after CNV onset was investigated by means of multiple linear regression analysis.
RESULTS: Seventy-seven of 81 eyes (95.1%) developed chorioretinal atrophy around myopic CNV during the follow-up period. Multiple linear regression revealed that age was the most influencing factor for the development of chorioretinal atrophy in all the subjects. When we divided the subjects into two groups according to their age, however, CNV size was the only factor to influence the development of chorioretinal atrophy in the patients younger than 40 years, whereas age was still the only influencing factor in those older than 40 years.
CONCLUSIONS: The factors influencing the development of chorioretinal atrophy differ according to patient age. Local factors, such as CNV size, determine the tendency to develop chorioretinal atrophy in young patients. Systemic factors, such as patient age, play a greater part in older subjects.

Entities:  

Mesh:

Year:  2003        PMID: 14648134     DOI: 10.1007/s00417-003-0803-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  16 in total

Review 1.  Ocular fluorometry: principles, fluorophores, instrumentation, and clinical applications.

Authors:  F Docchio
Journal:  Lasers Surg Med       Date:  1989       Impact factor: 4.025

2.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

Authors:  Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

3.  Inward and outward permeability of the blood-retinal barrier in experimental myopia.

Authors:  A Yoshida; S Ishiko; M Kojima
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

4.  Pathologic myopia and choroidal neovascularization.

Authors:  M L Hotchkiss; S L Fine
Journal:  Am J Ophthalmol       Date:  1981-02       Impact factor: 5.258

5.  On the definition of pathologic myopia in group studies.

Authors:  T Tokoro
Journal:  Acta Ophthalmol Suppl       Date:  1988

6.  Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization.

Authors:  H Tabandeh; H W Flynn; I U Scott; M L Lewis; P J Rosenfeld; F Rodriguez; A Rodriguez; L J Singerman; J Schiffman
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

7.  Etiology of choroidal neovascularization in young patients.

Authors:  S Y Cohen; A Laroche; Y Leguen; G Soubrane; G J Coscas
Journal:  Ophthalmology       Date:  1996-08       Impact factor: 12.079

8.  Subretinal hemorrhages with or without choroidal neovascularization in the maculas of patients with pathologic myopia.

Authors:  S Hayasaka; M Uchida; T Setogawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

9.  Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.

Authors:  J A Montero; J M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

10.  Prevalence of myopia in the United States.

Authors:  R D Sperduto; D Seigel; J Roberts; M Rowland
Journal:  Arch Ophthalmol       Date:  1983-03
View more
  13 in total

1.  Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization.

Authors:  Riyo Uemoto; Houmei Nakasato-Sonn; Tatsukata Kawagoe; Meguro Akira; Eiichi Okada; Nobuhisa Mizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-22       Impact factor: 3.117

Review 2.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

Review 3.  Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection.

Authors:  Jianghui Wang; Zefeng Kang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-25       Impact factor: 3.117

Review 4.  Recent trends in the management of maculopathy secondary to pathological myopia.

Authors:  D Mitry; H Zambarakji
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-13       Impact factor: 3.117

5.  Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization.

Authors:  Akio Oishi; Kenji Yamashiro; Akitaka Tsujikawa; Sotaro Ooto; Hiroshi Tamura; Isao Nakata; Masahiro Miyake; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-19       Impact factor: 3.117

6.  Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia.

Authors:  M Rinaldi; F Semeraro; F Chiosi; A Russo; M R Romano; M C Savastano; R dell'Omo; C Costagliola
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-28       Impact factor: 3.117

7.  Using optical coherence tomography angiography to guide myopic choroidal neovascularization treatment: a 3-year follow-up study.

Authors:  Tomoko Ueda-Consolvo; Noriko Shibuya; Toshihiko Oiwake; Shinya Abe; Ayaka Numata; Yuuki Honda; Shuichiro Yanagisawa; Atsushi Hayashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-06-18       Impact factor: 3.117

8.  Analysis of fundus shape in highly myopic eyes by using curvature maps constructed from optical coherence tomography.

Authors:  Masahiro Miyake; Kenji Yamashiro; Yumiko Akagi-Kurashige; Akio Oishi; Akitaka Tsujikawa; Masanori Hangai; Nagahisa Yoshimura
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

9.  Angiofluorographic Characteristics of Choroidal Neovascularization associated with Pathologic Myopia.

Authors:  Anca Tomi; Irina Ştefan
Journal:  Rom J Ophthalmol       Date:  2020 Oct-Dec

10.  Comparison of the efficacy of intravitreal ranibizumab for choroidal neovascularization due to pathological myopia with and without a dome-shaped macula.

Authors:  Bincui Cai; Jin Yang; Shuang Li; Linni Wang; Lu Chen; Xiaorong Li; Zhiqing Li
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.